Transthyretin (ATTR) Amyloidosis
View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.
Congresses
Transthyretin Amyloidosis (ATTR)
Heart Failure Association (HFA) 2025
Transthyretin Amyloidosis (ATTR)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025
Transthyretin Amyloidosis (ATTR)
American College of Cardiology (ACC) 2025
Transthyretin Amyloidosis (ATTR)
Société Francophone du Nerf Périphérique (SFNP) 2025
Transthyretin Amyloidosis (ATTR)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2024
Transthyretin Amyloidosis (ATTR)
American Heart Association (AHA) 2024
Publications
Transthyretin Amyloidosis (ATTR)
Effects of Vutrisiran on Cardiac Structure and Function in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Secondary Outcomes of the HELIOS-B Trial
Nature Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis: Post Hoc Analysis of APOLLO-B
JACC: Advances
Transthyretin Amyloidosis (ATTR)
Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis
Molecular Therapy Nucleic Acids
Transthyretin Amyloidosis (ATTR)
Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B
Journal of the American College of Cardiology
